Rheumatoid arthritis (RA) is an autoimmune disease that attacks joints. Psoriasis attacks the skin. But both involve TNF-alpha. The US tumor necrosis factor alpha inhibitors market research study shows that RA is the largest indication, but psoriasis is the fastest‑growing. Why? Because new biologics (IL‑17, IL‑23 inhibitors) are competing for psoriasis, but TNF inhibitors remain first‑line for RA.

What's the evidence? TNF inhibitors reduce joint damage in RA and clear skin in psoriasis. The US TNF-alpha inhibitors market trends highlight that the fastest‑growing end‑user segment is specialty clinics, which focus on rheumatology and dermatology, offering integrated care.

But TNF inhibitors have side effects: increased risk of infections (tuberculosis, fungal), and rare cases of lymphoma. That's why patients are screened for TB before starting.

The bottom line: if you have moderat❓ Frequently Asked Questions — US TNF-Alpha Inhibitors Market
What is the current size of the US TNF-alpha inhibitors market?
$5.07 billion in 2024. Full report: US TNF-alpha inhibitors market report.
Which drug class dominates?
Monoclonal antibodies. See the US TNF-alpha inhibitors market analysis.
Fastest‑growing drug class?
Fusion proteins. Check US TNF-alpha inhibitors market trends.
What is the projected market size by 2035?
$7.15 billion. Forecast in US TNF-alpha inhibitors market forecast.
Who are the key players in the US?
AbbVie, Amgen, J&J, Bristol-Myers Squibb. The US TNF-alpha inhibitors market research has full competitive landscape.e‑to‑severe RA or psoriasis, TNF inhibitors are a proven option. But they're not first‑line for mild disease.